Hypertrophic scarring

the greatest unmet challenge after burn injury

Celeste Finnerty, Marc G. Jeschke, Ludwik Branski, Juan P. Barret, Peter Dziewulski, David Herndon

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

Improvements in acute burn care have enabled patients to survive massive burns that would have once been fatal. Now up to 70% of patients develop hypertrophic scars after burns. The functional and psychosocial sequelae remain a major rehabilitative challenge, decreasing quality of life and delaying reintegration into society. Approaches to optimise healing potential of burn wounds use targeted wound care and surgery to minimise the development of hypertrophic scarring. Such approaches often fail, and modulation of the established scar is continued although the optimal indication, timing, and combination of therapies have yet to be established. The need for novel treatments is paramount, and future efforts to improve outcomes and quality of life should include optimisation of wound healing to attenuate or prevent hypertrophic scarring, well-designed trials to confirm treatment efficacy, and further elucidation of molecular mechanisms to allow development of new preventive and therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)1427-1436
Number of pages10
JournalThe Lancet
Volume388
Issue number10052
DOIs
StatePublished - Oct 1 2016

Fingerprint

Cicatrix
Burns
Wounds and Injuries
Quality of Life
Hypertrophic Cicatrix
Wound Healing
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hypertrophic scarring : the greatest unmet challenge after burn injury. / Finnerty, Celeste; Jeschke, Marc G.; Branski, Ludwik; Barret, Juan P.; Dziewulski, Peter; Herndon, David.

In: The Lancet, Vol. 388, No. 10052, 01.10.2016, p. 1427-1436.

Research output: Contribution to journalReview article

Finnerty, Celeste ; Jeschke, Marc G. ; Branski, Ludwik ; Barret, Juan P. ; Dziewulski, Peter ; Herndon, David. / Hypertrophic scarring : the greatest unmet challenge after burn injury. In: The Lancet. 2016 ; Vol. 388, No. 10052. pp. 1427-1436.
@article{9b86081c7ca241f19dbd7c044342ad8b,
title = "Hypertrophic scarring: the greatest unmet challenge after burn injury",
abstract = "Improvements in acute burn care have enabled patients to survive massive burns that would have once been fatal. Now up to 70{\%} of patients develop hypertrophic scars after burns. The functional and psychosocial sequelae remain a major rehabilitative challenge, decreasing quality of life and delaying reintegration into society. Approaches to optimise healing potential of burn wounds use targeted wound care and surgery to minimise the development of hypertrophic scarring. Such approaches often fail, and modulation of the established scar is continued although the optimal indication, timing, and combination of therapies have yet to be established. The need for novel treatments is paramount, and future efforts to improve outcomes and quality of life should include optimisation of wound healing to attenuate or prevent hypertrophic scarring, well-designed trials to confirm treatment efficacy, and further elucidation of molecular mechanisms to allow development of new preventive and therapeutic strategies.",
author = "Celeste Finnerty and Jeschke, {Marc G.} and Ludwik Branski and Barret, {Juan P.} and Peter Dziewulski and David Herndon",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/S0140-6736(16)31406-4",
language = "English (US)",
volume = "388",
pages = "1427--1436",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10052",

}

TY - JOUR

T1 - Hypertrophic scarring

T2 - the greatest unmet challenge after burn injury

AU - Finnerty, Celeste

AU - Jeschke, Marc G.

AU - Branski, Ludwik

AU - Barret, Juan P.

AU - Dziewulski, Peter

AU - Herndon, David

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Improvements in acute burn care have enabled patients to survive massive burns that would have once been fatal. Now up to 70% of patients develop hypertrophic scars after burns. The functional and psychosocial sequelae remain a major rehabilitative challenge, decreasing quality of life and delaying reintegration into society. Approaches to optimise healing potential of burn wounds use targeted wound care and surgery to minimise the development of hypertrophic scarring. Such approaches often fail, and modulation of the established scar is continued although the optimal indication, timing, and combination of therapies have yet to be established. The need for novel treatments is paramount, and future efforts to improve outcomes and quality of life should include optimisation of wound healing to attenuate or prevent hypertrophic scarring, well-designed trials to confirm treatment efficacy, and further elucidation of molecular mechanisms to allow development of new preventive and therapeutic strategies.

AB - Improvements in acute burn care have enabled patients to survive massive burns that would have once been fatal. Now up to 70% of patients develop hypertrophic scars after burns. The functional and psychosocial sequelae remain a major rehabilitative challenge, decreasing quality of life and delaying reintegration into society. Approaches to optimise healing potential of burn wounds use targeted wound care and surgery to minimise the development of hypertrophic scarring. Such approaches often fail, and modulation of the established scar is continued although the optimal indication, timing, and combination of therapies have yet to be established. The need for novel treatments is paramount, and future efforts to improve outcomes and quality of life should include optimisation of wound healing to attenuate or prevent hypertrophic scarring, well-designed trials to confirm treatment efficacy, and further elucidation of molecular mechanisms to allow development of new preventive and therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84994904491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994904491&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)31406-4

DO - 10.1016/S0140-6736(16)31406-4

M3 - Review article

VL - 388

SP - 1427

EP - 1436

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10052

ER -